LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fatty Acids Profiles Related to Biomarkers in GDM Progression

By LabMedica International staff writers
Posted on 25 Nov 2021
Print article
Image: The Hewlett Packard HP 5890 Series II Plus Gas Chromatograph (GC) System (Photo courtesy of American Laboratory Trading)
Image: The Hewlett Packard HP 5890 Series II Plus Gas Chromatograph (GC) System (Photo courtesy of American Laboratory Trading)
Gestational diabetes mellitus (GDM) is a condition in which a hormone made by the placenta prevents the body from using insulin effectively. Glucose builds up in the blood instead of being absorbed by the cells.

Fatty acids (FAs) are mainly composed of plasma phospholipids, cholesterol esters, triglycerides, and erythrocyte total phospholipids, all of which have been implicated in the pathogenesis of cardiometabolic disorders via their associations with insulin resistance, β-cell dysfunction, inflammation, glucose transporter inhibition, and lipotoxicity.

A team of medical scientists led by those at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Bethesda, MD, USA) recruited from a large cohort of 2,802 pregnant women, 85 GDM cases using the Carpenter and Coustan criteria and 85 non-GDM controls after exclusion. Upon enrollment at 8 to 13 weeks gestational age (GA) (visit 0), women were scheduled to attend five follow-up visits with blood collection at targeted weeks of GA.

The team examined three subclasses of plasma phospholipid FAs, including plasma phospholipid saturated FA (SFAs), polyunsaturated FA (PUFAs), and monounsaturated FAs (MUFAs) via the Hewlett Packard 5890 gas chromatography system (Palo Alto, CA, USA). The content of individual SFAs, PUFAs, and MUFAs was expressed as weight percentage of the total plasma phospholipid FAs. They assayed all case-control matched samples in a random order in the same analytic run and then performed 40 repeats in each batch among the in-house pooled control samples from the same cohort to assess the interassay CV.

The investigators reported that eight FAs showed significant fold changes from the baseline values (23–31 weeks) among GDM cases as compared to women without GDM. Five FAs showed reduced fold changes: myristic acid (14:0), palmitic acid (16:0), cis-palmitoleic acid (16:1n7), alpha-linolenic acid (18:3n3), and dihomo-gamma-linoleic acid (20:3n6), whereas three showed increases: heptadecanoic acid (17:0), cis-vaccenic acid (18:1n7), and arachidonic acid (20:4n6).

The authors concluded that they had identified eight plasma phospholipid FAs [SFAs: myristic acid (14:0), palmitic acid (16:0), and heptadecanoic acid (17:0); PUFAs: ALA (18:3n3), DGLA (20:3n6), and AA (20:4n6); MUFAs: palmitoleic acid (16:1n7) and vaccenic acid (18:1n7)] with unique patterns of change before and after GDM diagnosis. Such changes of FAs differed significantly between women with and without GDM during the same time window in pregnancy. The study was published on October 11, 2021 in the journal Clinical Chemistry.

Related Links:
National Institute of Child Health and Human Development
Hewlett Packard


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.